We are an alliance of European patient associations representing those affected by LAMA2-Congenital Muscular Dystrophy (LAMA2-CMD), also known as Merosin-Deficient Muscular Dystrophy (MDC1A).
An overview of the different partners and collaborators involved in driving this initiative forward can be found below.
This website was made possible thanks to the financial support of Prothelia and ImpulsaT, biopharmaceutical companies developing therapies for LAMA2-CMD.
Our mission is to further advance awareness and research for LAMA2-CMD internationally and to directly support patients and families by providing relevant information and resources.
By including the patients and families, and by collaborating with the clinicians, researchers and members of the biotech industry involved with LAMA2-CMD around the world, we aim to accelerate the road to therapy in a truly united and collective global effort.
Together, we are dedicated towards achieving the following goals:
If you have any questions we encourage you to contact us here, or by using the contact form below.